Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term Terhi T. Piltonen,

Slides:

Advertisements

Similar presentations

Charles J. Glueck, M. D. , Joel Pranikoff, M. D. , Dawit Aregawi, M. D

Advertisements

Longitudinal assessment of circulating insulin-like peptide 3 levels in healthy peripubertal girls Casper P. Hagen, Ph.D., Mikkel G. Mieritz, M.D., John.

Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the.

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Andrew J. Krentz, M.D., Elizabeth Barrett-Connor, M.D.

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Efficacy of predictive models for polycystic ovary syndrome using serum levels of two antimüllerian hormone isoforms (proAMH and AMHN,C) Michael W. Pankhurst,

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

Female exposure to phenols and phthalates and time to pregnancy: the Maternal-Infant Research on Environmental Chemicals (MIREC) Study Maria P. Vélez,

Longitudinal assessment of circulating insulin-like peptide 3 levels in healthy peripubertal girls Casper P. Hagen, Ph.D., Mikkel G. Mieritz, M.D., John.

Endocrine and cardiometabolic cord blood characteristics of offspring born to mothers with and without polycystic ovary syndrome Nadine M.P. Daan, M.D.,

Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries Robert L. Rosenfield, M.D., Kristen Wroblewski,

Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis Anuja Dokras, M.D., Ph.D., Shari.

Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis Héctor F. Escobar-Morreale, M.D., Ph.D., Manuel Luque-Ramírez,

Ovarian reserve and subsequent assisted reproduction outcomes after methotrexate therapy for ectopic pregnancy or pregnancy of unknown location Micah.

Decreased inhibin B responses following recombinant human chorionic gonadotropin administration in normal women and women with polycystic ovary syndrome

H. Irene Su, M. D. , M. S. C. E. , Mary D. Sammel, Sc. D. , Michael V

Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life Pekka Pinola, Ph.D., Katri Puukka,

Low concentration of circulating antimüllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study

The association between circulating levels of antimüllerian hormone and follicle number, androgens, and menstrual cycle characteristics in young women

Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism

Antimüllerian hormone levels decrease in women using combined contraception independently of administration route Sanna Kallio, M.D., Johanna Puurunen,

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

Antimüllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause Linlin Cui, M.D., Ph.D., Yingying.

Comparative assessment of five serum antimüllerian hormone assays for the diagnosis of polycystic ovary syndrome Pascal Pigny, Ph.D., Elisse Gorisse,

Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women Carlos Iglesias, M.D., Manish Banker, M.D.,

Role of ovarian reserve markers, antimüllerian hormone and antral follicle count, as aneuploidy markers in ongoing pregnancies and miscarriages Maribel.

Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women Ellen W. Freeman, Ph.D.,

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Alexandra Rousseau, M. Sc. , Fida Ayoubi, M. Sc

Robert A. Wild, M. D. , Manfredi Rizzo, M. D. , Sheri Clifton, Ph. D

Study of circulating hepcidin in association with iron excess, metabolic syndrome, and BMP-6 expression in granulosa cells in women with polycystic ovary.

Orhan Bukulmez, M. D. , Qin Li, M. S. , Bruce R. Carr, M. D

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

Clinical course of depression symptoms and predictors of enduring depression risk in women with polycystic ovary syndrome: Results of a longitudinal study

Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the.

Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhea Hang Wun Raymond Li,

CYP11A1 and CYP17 promoter polymorphisms associate with hyperandrogenemia in polycystic ovary syndrome Madhavi Pusalkar, M.Sc., Pervin Meherji, M.D.,

Epigenetic regulation of an adverse metabolic phenotype in polycystic ovary syndrome: the impact of the leukocyte methylation of PPARGC1A promoter Hongcui.

Serum antimüllerian hormone levels are independently related to miscarriage rates after in vitro fertilization–embryo transfer Bruno Tarasconi, M.D.,

Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome Annie A. Guedikian, B.S.,

Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular.

Polycystic ovary morphology: age-based ultrasound criteria

Andrew C. Bjonnes, M.S., Richa Saxena, Ph.D., Corrine K. Welt, M.D.

Polycystic ovary syndrome offspring display increased oxidative stress markers comparable to gestational diabetes offspring Georgios Boutzios, M.D.,

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D.

Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis Reshef Tal,

Testosterone levels in pregnant women correlate with the insulin response during the glucose tolerance test Anuja Dokras, M.D., Ph.D., Robert Z Spaczynski,

Increased secretion of amylin in women with polycystic ovary syndrome

Prevalence of polycystic ovary syndrome in adolescents

Antoni J. Duleba, M.D., Ibrahim M. Ahmed, M.D. Fertility and Sterility

Luteal support with intravaginal progesterone increases clinical pregnancy rates in women with polycystic ovary syndrome using letrozole for ovulation.

Impact of laparoscopic ovarian drilling on anti-Müllerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women.

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Circulating microRNAs as potential biomarkers for endometriosis

Paolo Moghetti, M.D. Fertility and Sterility

Clinical and biologic evaluation of ovarian function in women treated by bone marrow transplantation for various indications during childhood or adolescence

Impact of subclinical hypothyroidism in women with recurrent early pregnancy loss Lia A. Bernardi, M.D., Ronald N. Cohen, M.D., Mary D. Stephenson, M.D.,

Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with.

Martha Luna, M. D. , Marlena Duke, M. Sc. , Alan Copperman, M. D

Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome Yuwen Wu, M.D., Jianhua Zhang,

Touraj Mahmoudi, M. Sc. , Hamid Gourabi, Ph. D. , Mahnaz Ashrafi, M. D

High singleton live birth rate confirmed after ovulation induction in women with anovulatory polycystic ovary syndrome: validation of a prediction model.

Divergent effects of the 677C>T mutation of the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene on ovarian responsiveness and anti-Müllerian hormone.

Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients Artemis Karkanaki,

Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome Robert P. Kauffman,

Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome Kevin H. Maas, M.D., Ph.D., Sandy Chuan,

Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization Rongrong Tan, M.M.Sc., Danhua Pu,

Presentation transcript:

Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term Terhi T. Piltonen, M.D., Ph.D., Paolo Giacobini, Ph.D., Åsa Edvinsson, M.Sc., Steinar Hustad, Ph.D., Susanne Lager, Ph.D., Laure Morin-Papunen, M.D., Ph.D., Juha S. Tapanainen, M.D., Ph.D., Inger Sundström-Poromaa, M.D., Ph.D., Riikka K. Arffman, Ph.D. Fertility and Sterility Volume 111, Issue 3, Pages 588-596.e1 (March 2019) DOI: 10.1016/j.fertnstert.2018.11.028 Copyright © 2018 The Authors Terms and Conditions

Figure 1 (A) Levels of AMH were significantly higher in women with PCOS (n = 25) than in control women (n = 49) at term. (B) AMH levels of women carrying a female fetus (n = 34) were higher than those of women carrying a male fetus (n = 41). The horizontal line in each plot corresponds to the median value. The vertical line represents the 25th–75th percentile range. Comparisons between groups were performed using unpaired nonparametric two-tailed Mann–Whitney U tests. *P<.05; ***P<.001. Fertility and Sterility 2019 111, 588-596.e1DOI: (10.1016/j.fertnstert.2018.11.028) Copyright © 2018 The Authors Terms and Conditions

Figure 2 Differences in levels of AMH, A, T, and E2 between women with PCOS and controls, according to gender of the offspring. The data showed significant differences in AMH and steroid hormone levels, especially in pregnancies with a female fetus. Numbers of subjects in groups for AMH analysis (A): all (PCOS = 25, control = 49), women with a female fetus (PCOS = 8, control = 25), women with a male fetus (PCOS = 17, control = 24). Numbers of subjects in groups for steroid analysis (B–D): all (PCOS = 23, control = 45), women with a female fetus (PCOS = 8, control = 24), women with a male fetus (PCOS = 16, control = 19). The box represents the 25th–75th percentile range and the horizontal line the median. The whiskers represent minimum and maximum values. Differences between groups were determined by using nonparametric Mann–Whitney U tests. *P<.05; **P<.01. Fertility and Sterility 2019 111, 588-596.e1DOI: (10.1016/j.fertnstert.2018.11.028) Copyright © 2018 The Authors Terms and Conditions

Supplemental Figure 1 Maternal age correlated with square-root-transformed AMH levels only in the control group and not in women with PCOS. There was a significant difference between the slopes (studied by analysis of covariance). The correlations between AMH and gestational length were nonsignificant and equal in both groups. PCOS, black circles (●), continuous line; controls, white circles (○), dotted line. Fertility and Sterility 2019 111, 588-596.e1DOI: (10.1016/j.fertnstert.2018.11.028) Copyright © 2018 The Authors Terms and Conditions